CanSinoBIO Kicks-off the Polio VLP Vaccine Cooperation

December 1, 2023 – CanSino Biologics Inc. ("CanSinoBIO" or "the Company") kicked off its innovative Polio VLP Vaccine Cooperation that aims to eradicate polio worldwide today as representatives from The Bill & Melinda Gates Foundation (the foundation) visited the facility.


Dr. Xuefeng Yu, Chairman and CEO, Dr. Shoubai Chao, Chief Operating Officer, Dr. Tao Zhu, Chief Scientific Officer, and Ms. Jing Wang, Chief Commercial Officer and representatives from CanSinoBIO gave warm welcome to the foundation delegation.

Dr. Xuefeng Yu expressed his gratitude to the foundation for their support over the past years that enabled CanSinoBIO to play a vital role in the global polio eradication efforts. CanSinoBIO is committed to continuously focusing on this fight against the vaccine-preventable disease and make a greater impact on global public health. 


CanSinoBIO has been actively participating in the World Health Organization (the WHO) polio eradication strategy to eliminate the disease, and has been focusing on the needs of the underserved countries and regions. CanSinoBIO tends to seek for more support from the foundation to advance the development and global access of innovative vaccines.





Following the meeting, the foundation representatives toured the vaccine industrialization facility located in the headquarter of CanSinoBIO, where they had a better understanding of the Company’s research innovation and capacities.


Based on its protein structure design and VLP assembly technology platform, CanSinoBIO has developed an innovative vaccine for polio, VLP-IPV. It is a non-infectious vaccine that does not require live virus for development and production. The vaccine is expected to have significant safety and immunogenicity profile.

Polio, a disease that can cause disability and death, still threats hundreds of thousands of children and families. The WHO recommends the non-infectious polio vaccine as a preferred solution in post era of polio eradication. As an innovative biopharmaceutical company in China, CanSinoBIO is currently in the "last mile" of the polio eradication campaign.  Together with support from the foundation and  partners around the world, the Company is dedicated to accelerating the process and ensuring global equitable access to innovative, high-quality, and affordable vaccines.

About CanSinoBIO

Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to providing high-quality, innovative, and affordable vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a rich portfolio of a pipeline products preventing more than 10 diseases, including the Aisa's first vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia® approved in over 10 countries and granted EUL by the WHO, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia® and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia® approved by NMPA in China. The world's first inhaled COVID-19 vaccine Convidecia Air® has been approved as a booster dose in China, Morocco, and Indonesia. Additional information can be found online at